Specifically, in cases such as pancreatic ductal adenocarcinoma, Monalizumab (IPH2201), a human IgG4 blocking monoclonal antibody targeting inhibitory NKG2A on NK cells and a subset of CD8+ T cells, disrupts the interaction between inhibitory NKG2A and HLA-E. This evidence concerns the gene KLRC1 and pancreatic ductal adenocarcinoma.